Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010–2011
- 18 February 2014
- journal article
- Published by Taylor & Francis Ltd in Journal of Chemotherapy
- Vol. 27 (2), 67-73
- https://doi.org/10.1179/1973947814y.0000000164
Abstract
The study for monitoring antimicrobial resistance trends (SMART) surveillance program monitors the epidemiology and trends in antibiotic resistance of intra-abdominal pathogens to currently used therapies. The current report describes such trends during 2010-2011. A total of 25,746 Gram-negative clinical isolates from intra-abdominal infections were collected and classified as hospital-associated (HA) if the hospital length of stay (LOS) at the time of specimen collection was ≥48 hours, community-associated (CA) if LOS at the time of specimen collection was <48 hours, or unknown (no designation given by participating centre). A total of 92 different species were collected of which the most common was Escherichia coli: 39% of all isolates in North America to 55% in Africa. Klebsiella pneumoniae was the second most common pathogen: 11% of all isolates from Europe to 19% of all isolates from Asia. Isolates were from multiple intra-abdominal sources of which 32% were peritoneal fluid, 20% were intra-abdominal abscesses, and 16.5% were gall bladder infections. Isolates were further classified as HA (55% of all isolates), CA (39% of all isolates), or unknown (6% of all isolates). The most active antibiotics tested were imipenem, ertapenem, amikacin, and piperacillin-tazobactam. Resistance rates to all other antibiotics tested were high. Considering the current data set and high-level resistance of intra-abdominal pathogens to various antibiotics, further monitoring of the epidemiology of intra-abdominal infections and their susceptibility to antibiotics through SMART is warranted.Keywords
This publication has 13 references indexed in Scilit:
- Trending Eight Years ofIn VitroActivity of Ertapenem and Comparators AgainstEscherichia Colifrom Intra-abdominal Infections in North America—SMART 2002-2009Journal of Chemotherapy, 2011
- Epidemiologic Trends, Occurrence of Extended-Spectrum β-Lactamase Production, and Performance of Ertapenem and Comparators in Patients with Intra-Abdominal Infections: Analysis of Global Trend Data from 2002–2007 from the SMART StudySurgical Infections, 2010
- Incidence and Antimicrobial Susceptibility of Escherichia coli and Klebsiella pneumoniae with Extended-Spectrum β-Lactamases in Community- and Hospital-Associated Intra-Abdominal Infections in Europe: Results of the 2008 Study for Monitoring Antimicrobial Resistance Trends (SMART)Antimicrobial Agents and Chemotherapy, 2010
- Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infectionJournal of Antimicrobial Chemotherapy, 2010
- Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United KingdomJournal of Antimicrobial Chemotherapy, 2008
- Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratoryInternational Journal of Antimicrobial Agents, 2007
- CTX-M: changing the face of ESBLs in EuropeJournal of Antimicrobial Chemotherapy, 2006
- The Impact of Surgical-Site Infections in the 1990s: Attributable Mortality, Excess Length of Hospitalization, And Extra CostsInfection Control & Hospital Epidemiology, 1999
- The Price of a Surgical-Site Infection: More Than Just Excess Length of StayInfection Control & Hospital Epidemiology, 1999